

Signs of bronchiectasis

Bronchiectasis is confirmed with a high resolution CT scan. Patients with confirmed bronchiectasis can benefit from starting vest therapy soon after diagnosis and before pulmonary function worsens.

With consistent, daily vest therapy, the following benefits may be experienced:

Better respiratory health

Fewer unscheduled visits to specialists and doctors¹¹

Reduced hospitalizations due to respiratory complications^{11,12}

A decrease in medications used for respiratory conditions¹¹

Lower incidence of pneumonias⁸

Better quality of life

Decreased⁷ and more productive cough¹³

Improved breathing capacity on lung function tests¹⁴

Increased activity and exercise capacity and tolerance¹⁵

11. Giarraffa P, Berger KI, Chaikin AA, Axelrod FB, Davey C, Becker B. Assessing efficacy of high-frequency chest wall oscillation in patients with familial dysautonomia. CHEST 2005;128:3377-3381. Note: Year-long study of 15 patients with pulmonary disease due to Riley-Day syndrome.

12. Overgaard PM, Radford PJ. High-frequency chest wall oscillation improves outcomes in children with cerebral palsy. CHEST 2005; 128 (4): 354S. Note: A retrospective quality assurance review on 13 children with cerebral palsy.

13. Hansen LG, Warwick WJ. High-frequency chest compression system to aid in clearance of mucus from the lung. Biomed Instrum Technol. 1990;24(4):289-294.

14. Warwick WJ, Hansen LG. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr Pulmonol. 1991;11(3):265-271.

15. Rumback M. In a 90-day trial of HFCC/HFCWO, COPD patients electing to continue therapy experienced significant improvements in dyspnea, exercise tolerance and quality of life. Chest. 2001;120(4):250S. (POSTER) Note: 85 COPD patients.

We're here to help

We recognize the healthcare environment can be complicated. We are here to help make your experience as easy and stress free as possible.

RespirTech's nationwide network of healthcare professionals is ready to assist with everything from training patients and caregivers on how to use the Philips InCourage system, to sorting out insurance coverage and explaining your insurance benefits.

"The service has been great, the staff has helped us navigate the health insurance maze and if we ever have questions, we get a very prompt response. I highly recommend the InCourage system."

– Jennifer F., CA

"Anyone with COPD or bronchiectasis knows how debilitating it can be – it completely wipes you out. Antibiotics were a way of life for me."

Once I received my InCourage therapy vest, within the first week I noticed that clearing my lungs was extremely easy. No antibiotics*, no lung infections since starting using the vest."

– Autum E., PA,
COPD & bronchiectasis

*Individual results may vary



RespirTech®

Respiratory Technologies Inc., d.b.a. RespirTech

Toll free: 800.793.1261

Main: 651.379.8999

Fax: 866.727.3235

www.respirtech.com

5905 Nathan Lane North,
Suite 200, Plymouth, MN
55442

Connect with us –



Better breathing for better living

Vest therapy for treatment of chronic lung disease

RespirTech

Treating your COPD and still struggling?

Chronic productive cough?
Repeated antibiotic use for chest infections?

These may be indicators of bronchiectasis (BE)—a common but frequently undiagnosed condition caused by chronic inflammation of the airways.¹

It's estimated that half of people living with serious COPD may have BE.²



Symptoms that may be indicators of BE include:

- Declining lung function²
- Chronic productive cough³
- Chronic mucus secretion of sputum (phlegm)³
- Repeat antibiotic use for chest infections^{2,4}
- Need for supplemental oxygen^{2,4}
- One or more hospitalizations in the last year^{2,4}

Airway clearance therapy can help

Chronic lung conditions like COPD, chronic bronchitis and bronchiectasis can result in excess mucus and difficulty clearing the airways.

While there is no cure for patients diagnosed with BE, early detection and airway clearance therapy can lead to a better quality of life and slow or prevent future lung damage.⁵ The goal is to clear out mucus before it builds up, making it harder for bacteria to grow.

Treatments like vest therapy can help break this serious cycle of excess mucus, lung infection and further lung damage.⁶

Philips InCourage vest therapy

Creates compressions to the chest, helping to loosen, thin and move mucus through the lungs and out of the airways.



Active venting

Designed to immediately release air in the vest in response to the user's breath so the vest feels less constricted allowing a deeper inhale

The most vest sizes

23 different sizes offer an optimized fit for chests measuring 16-60"

Quickfit sizing

Tailored, repeatable fit for consistent therapy

Machine washable

Machine wash and dry without disassembly

User-friendly control panel

One-button start and simple programming

Locking hose connectors

Provide a fast, simple and secure connection

More comfort for better outcomes

Comfort



Active venting is designed for a deep, comfortable breath during therapy



Adherence



More comfort helps encourage therapy adherence



Outcomes



Vest therapy helps improve breathing,⁷ reduce lung infections⁸ and hospitalizations⁹



"I was on antibiotics every month for the last 40 years. I've used the InCourage system for over two years [and] I haven't had to take antibiotics."

I have so much more energy, more of the desire to want to do things. It's completely changed my life."

– Marjorie M., CA, Bronchiectasis patient

*Individual results may vary

9. Barto T, et al. Registry Outcomes for HFCWO Vest Therapy in Adult Patients with Bronchiectasis. Poster presented at: Am Thor Soc Intern Confer; 15 May 2016; San Francisco, Calif. Note: 2596 BE patient registry study comparing hospitalizations, antibiotic use and self-reported QOL metrics before and after HFCWO therapy.

Better clearance

Research has shown triangular waveform technology clears up to 20% more mucus than competing technology.¹⁰



RespirTech's patient outcomes program* has self-reported data from 18,000+ bronchiectasis patients & counting

Patient-reported results after 12 months of vest therapy with the Philips InCourage system showed:



Yearly hospitalization rate decreased

↓ 62%




Ability to clear lungs "good-excellent" rating increased

↑ 63%



Respiratory health "good-excellent" rating increased

↑ 45%



Antibiotic use decreased

↓ 13%

1. Maselli DJ, Amalakuhan B, Keyt H, Diaz AA. Suspecting non-cystic fibrosis bronchiectasis: What the busy primary care clinician needs to know. Int J Clin Pract. 2017;71(2):e12924.

2. Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:823–831.

3. King P. Pathogenesis of bronchiectasis. Paediatr Respir Rev. e011;12(2):104–110.

4. Weycker D E, J, Oster G, Tino G. Prevalence and Economic Burden of Bronchiectasis. Clin Pulm Med. 2005;12(4):205–209.

5. American Thoracic Society. ATS Patient Education Series. Am J Respir Crit Care Med 2017;195:15–16.

6. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3).

7. Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med. 2013;13:21. Note: 37 BE patient study comparing HFCC, OPEP or no-ACT.

8. Plioplys AV, Lewis S, Kasnicka I. Pulmonary vest therapy in pediatric long-term care. J Am Med Dir Assoc 2002;3:318–321. Note: Study of 7 quadriplegic cerebral palsy patients, 4 having epilepsy.

10. Milla CE, Hansen LG, Weber A, Warwick WJ. High-Frequency chest compression: effect of the third generation compression waveform. Biomed Instrum Technol 2004; 38:322–328. Note: 8 CF patient study comparing triangular vs. sine waveform technology.

*Methodology: Phone surveys at regular intervals with bronchiectasis patients using the InCourage system. Data collection began in 2013. As of 3/31/2020, 17,943 patients completed the baseline survey; 11,629 patients in 1-month cohort; 7,982 in 6-month cohort; 5,903 in 12-month cohort. The Bronchiectasis outcomes registry consists of 20,062 patient to date.